Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2000 Feb;74(4):1694-703.
doi: 10.1128/jvi.74.4.1694-1703.2000.

Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine

H Gahéry-Ségard  1 , G Pialoux, B Charmeteau, S Sermet, H Poncelet, M Raux, A Tartar, J P Lévy, H Gras-Masse, J G Guillet
Affiliations
Clinical Trial

Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine

H Gahéry-Ségard et al. J Virol. 2000 Feb.

Abstract

We have attempted to develop an anti-human immunodeficiency virus (HIV) lipopeptide vaccine with several HIV-specific long peptides modified by C-terminal addition of a single palmitoyl chain. A mixture of six lipopeptides derived from regulatory or structural HIV-1 proteins (Nef, Gag, and Env) was prepared. A phase I study was conducted to evaluate immunogenicity and tolerance in lipopeptide vaccination of HIV-1-seronegative volunteers given three injections of either 100, 250, or 500 microg of each lipopeptide, with or without immunoadjuvant (QS21). This report analyzes in detail B- and T-cell responses induced by vaccination. The lipopeptide vaccine elicited strong and multiepitopic B- and T-cell responses. Vaccinated subjects produced specific immunoglobulin G antibodies that recognized the Nef and Gag proteins. After the third injection, helper CD4(+)-T-cell responses as well as specific cytotoxic CD8(+) T cells were also obtained. These CD8(+) T cells were able to recognize naturally processed viral proteins. Finally, specific gamma interferon-secreting CD8(+) T cells were also detected ex vivo.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Immunoblot pattern of serum specific for Nef protein. Suspensions of recombinant NEF protein (10 μl) harvested from E. coli production were separated by SDS-PAGE. Sera (diluted 1/100) collected from volunteers before (W0) and after (W20) immunization were tested and revealed with a sheep horseradish peroxidase-labeled anti-human immunoglobulin conjugate (1/2,000).
FIG. 2
FIG. 2
Patterns of IgG specific for Gag protein were detected by using a commercial kit (New Lav Blot I; see Materials and Methods). Sera (diluted 1/100) collected from volunteers at different time points (W0 and W20) were tested for the presence of anti-HIV-1 Gag protein IgG antibodies. We could detect the mature Gag protein (P25) and the two precursors (P40 and P55).
FIG. 3
FIG. 3
The positive anti-N1, anti-G2, and anti-E CTL obtained after four stimulations with PBMC (W20) from volunteer V4.1 (results shown in Table 5) were stimulated one more time with the respective long peptides to obtain more cells. To determine the fine nature of effector cells in response to these peptides, T-cell depletion was performed with anti-CD4 or anti-CD8 antibodies and complement 1 week after the last stimulation. Target cells (EBV infected) were sensitized with the N1 (A), G2 (B), or E (C) long peptides. The HIV-1-specific CTL from volunteer V4.1 were analyzed at an E/T ratio of 1.5:1 to 40:1.
FIG. 4
FIG. 4
Anti-NEF CTL obtained with PBMC from volunteers V4.5 were tested for their capacities to recognize autologous EBV-infected targets infected with different recombinant Nef vaccinia viruses. For the same E/T ratio (16:1), the Nef peptide-specific CTL were tested against recombinant Nef proteins derived from HIV-1 LAI and MN (clade B), HIV-1 Bangui (clade A), and HIV-2 ROD.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. BenMohamed L, Gras-Masse H, Tartar A, Daubersies P, Brahimi K, Bossus M, Thomas A, Druilhe P. Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees. Eur J Immunol. 1997;27:1242–1253. - PubMed
    1. Clements-Mann M L, Weinhold K, Matthews T J, Graham B S, Gorse G J, Keefer M C, McElrath M J, Hsieh R H, Mestecky J, Zolla-Pazner S, Mascola J, Schwartz D, Siliciano R, Corey L, Wright P F, Belshe R, Dolin R, Jackson S, Xu S, Fast P, Walker M C, Stablein D, Excler J L, Tartaglia J, Paoletti E A. v. e. Group. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1 MN gp120, HIV-1 SF2 recombinant gp120, or both vaccines in seronegative adults. J Infect Dis. 1998;177:1230–1246. - PubMed
    1. Connan F, Hlavac F, Hoebeke J, Guillet J G, Choppin J. A simple assay for detection of peptides promoting the assembly of HLA class I molecules. Eur J Immunol. 1994;24:777–780. - PubMed
    1. Connor R, Korber B, Graham B, Hahn B, Ho D D, Walker B, Neumann A, Vermund S, Mestecky J, Jackson S, Fenamore E, Cao Y, Gao F, Kalams S, Kunstman K, McDonald D, McWilliams N, Trkola A, Moore J, Woonsky S. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J Virol. 1998;72:1552–1576. - PMC - PubMed
    1. Couillin I, Culmann-Penciolelli B, Gomard E, Choppin J, Levy J P, Guillet J G, Saragosti S. Impaired CTL recognition due to genetic variations in the main immunogenic region of the HIV-1 Nef protein. J Exp Med. 1994;180:1129–1134. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources

-